References Insel TR, Cuthbert BN
Oral cyanocobalamin/SNAC may offer a less invasive option for seniors needing consistent therapy without injections
Evolution of nanomedicines for the treatment of autoimmune disease: From vehicles for drug delivery to inducers of bystander immunoregulation
Our peptides are sourced from trusted manufacturing partners and produced in controlled laboratory environments to support reliable, repeatable research outcomes
Our findings, mirror the differences of Stage 2 or Stage 3 siblings when independently measured and show dramatic and statistically significant reductions of GPx3 in the most severely affect children ( p = 2.47 10 8 , Paired t-test) again with non-overlapping 95% confidence intervals (95% CI Unaffected Stage 2/3 [1.7 ug/ml, 2.1 ug/ml], 95% CI Konzo Stage 2/3 [0.98 ug/ml, 1.3 ug/ml]) (Fig
Acknowledgements We thank Drs